• 1

    American Public Health Association: Deep-vein thrombosis: advancing awareness to protect patient lives. Paper presented at the Public Health Leadership Conference on Deep-Vein Thrombosis, February 26. ,2003. , Washington, DC.

  • 2

    American Public Health Association and Wirthlin Worldwide: APHA deep-vein thrombosis omnibus survey. Available at: http://www.apha.org/ppp/dvt_white_paper.pdf. Accessed May 23. ,2004. .

  • 3

    La Pointe KJ, Cappuzzo KA, Hamilton CW: Low molecular weight heparins for deep vein thrombosis. Available at: http://www.uspharmacist.com/oldformat.asp?url=newlook/files/feat/lmwh.htm. Accessed April 25. ,2004. .

  • 4

    Lensing AW, Prandoni P, Prins MH, et al: Deep-vein thrombosis. .Lancet 353::479. ,1999. .

  • 5

    Janssen MC, Haenen JH, van Asten WN, et al: Clinical and haemodynamic sequelae of deep venous thrombosis: retrospective evaluation after 7–13 years. .Clin Sci Lond 93::7. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Weitz JI: Low molecular weight heparins. .N Engl J Med 337::688. ,1997. .

  • 7

    Yeager BF, Matheny SC: Low-molecular-weight heparin in outpatient treatment of DVT. .Am Fam Physician 59::945. ,1999. .

  • 8

    Rydberg EJ, Westfall JM, Nicholas RA: Low-molecular-weight heparin in preventing and treating DVT. .Am Fam Physician 59::1607. ,1999. .

  • 9

    Nutescu EA: Antithrombotic therapy for the prevention of venous thromboembolism. Available at: http://www.uspharmacist.com/print.asp?page=ce/antithrombotic/default.htm. Accessed April 16. ,2004. .

  • 10

    Anderson FA, Wheeler HB: Venous thromboembolism: risk factors and prophylaxis. .Clin Chest Med 16::235. ,1995. .

  • 11

    Erdman SM, Chuck SK, Rodvold KA: “Thromboembolic Disorders,” in Pharmacotherapy: A Pathophysiological Approach, 4th Ed, ed by JT DiPiro, et al, p 295, Appleton & Lange, Stamford, CT. ,1999. .

  • 12

    Harenberg J, Huck K, Bratsch H, et al: Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. .Haemostasis 20: (suppl 1) :205. ,1990. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Harenberg J: Pharmacology of low molecular weight heparins. .Semin Thromb Hemost 16. (suppl 12):1990. .

  • 14

    Hirsh J, Anand SS, Halperin JL, et al: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. .Arterioscler Thromb Vasc Biol 27::e9. ,2001. .

    • Search Google Scholar
    • Export Citation
  • 15

    Cornelli U, Fareed J: Human pharmacokinetics of low molecular weight heparins: applied and clinical considerations. .Semin Thromb Hemost 25: (suppl 3):57. ,1999. .

    • Search Google Scholar
    • Export Citation
  • 16

    Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics and metabolism in humans. .Haemostasis 26: (suppl 2):24. ,1996. .

  • 17

    Duplaga BA, Rivers CW, Nutescu E: Dosing and monitoring of low-molecular-weight heparins in special populations. .Pharmacotherapy 21::218. ,2001. .

  • 18

    Palacioz K: Dosing of enoxaparin (Lovenox®) in special patient populations. Pharmacist’s Letter/Prescriber’s. Letter 20: (February):1. ,2004. .

    • Search Google Scholar
    • Export Citation
  • 19

    Murray L (ed): Physicians’ Desk Reference, 58th Ed, pp 748, 2399, 2672, Thomson PDR, Montvale, NJ. ,2004. .

  • 20

    Novak KK (ed): Drug Facts and Comparisons: Updated Monthly, pp 163, 165, 165a, 166, Wolters Kluwer Health Inc, St Louis. ,2004. .

  • 21

    Wade WE, Martin BC, Kotza JA, et al: Formulary management of low molecular weight heparins. .Pharmacoeconomics 17::1. ,2000. .

  • 22

    McEvoy GK: AHFS Drug Information, American Society of Health-System Pharmacists, Bethesda, MD. ,2004. .

  • 23

    Cadroy Y, Pourrat J, Baladre MF, et al: Delayed elimination of enoxaparin in patients with chronic renal insufficiency. .Thromb Res 63::385. ,1991. .

  • 24

    Scholten DJ, Hoedema RM, Scholten SE: A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. .Obes Surg 21::19. ,2002. .

    • Search Google Scholar
    • Export Citation

Low-Molecular-Weight Heparins

An Overview for the Podiatric Physician

Robert G. Smith Private practice, Shoe String Podiatry, 723 Lucerne Cir, Ormond Beach, FL 32174.

Search for other papers by Robert G. Smith in
Current site
Google Scholar
 DPM, RPh, CPed
View More View Less

Deep venous thrombosis is a common but underdiagnosed medical condition. The epidemiologic features, economic impact, morbidity, and mortality of venous thromboembolism make it imperative that the podiatric physician be familiar with its pathogenesis as well as its pharmacologic treatment. Medical literature rooted in clinical evidence has demonstrated that low-molecular-weight heparins are safe and effective for the prevention and treatment of venous thromboembolism. The primary purpose of this article is to review the pharmacologic characteristics of low-molecular-weight heparins. Dosing recommendations for low-molecular-weight heparins as they apply to the prevention of deep venous thrombosis are presented. Finally, a dosing criteria chart is presented to assist the podiatric physician in prescribing and evaluating low-molecular-weight heparins as a therapeutic class. (J Am Podiatr Med Assoc 95(4): 383–389, 2005)